explore -WSS

explore

author：leisure time 2025-08-25 07:28:19 - browse：6137

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Companies helping big Covid

knowledge

WSS

Hospital price transparency does save money, advocate argues

Watch the official trailer for 'Ahsoka' series

STAT Summit: Michael J. Fox on progress in Parkinson's research

China sends large group of warplanes, navy ships towards Taiwan in forceful display

FDA gives detailed accounting of AI

Vermont grapples with historic flooding as more rainstorms head for Northeast

entertainment

explore

hotspot

Activists slam private health insurers over coverage restrictions

France's anti

Psychedelics group wrestles with new pharma identity

2023 STAT Wunderkinds: get to know the winners

As demand for Covid shots wanes, Moderna seeks its next success

Cuban government calls US nuclear submarine stop a 'provocative escalation'

Anesthesiologist group: stop taking Ozempic before surgery

Pharmacists can make shortage drugs, but at what cost?

The high cost of giving birth even with insurance

The EU Joint Clinical Assessment needs to live up to its promise

hotspot

After half a century, Israel moves to evict squatter from his cave home on the beach

STAT Summit: GSK CEO on pharma giant's new direction

Grail's uphill battle for Medicare to cover its cancer screening test

Eli Lilly expects to double planned employment in Boston center

Tommy Tuberville reverses his claim that white nationalists are unfairly labeled racist

NIH confirmation hearing shows politicization of research

Wikipedia

knowledge

Wikipedia

explore